Jefferies Maintains Hold on ResMed, Lowers Price Target to $225

Benzinga Newsdesk www.benzinga.com Negative 78.4%

Neg 78.4% Neu 0% Pos 0%

Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $240 to $225.

Comments

No comments yet. Be the first!